Between the four anti-PD-1/PD-L1 agents that are most advanced in terms of clinical development, it would appear that every standard of care chemotherapy regimen in every tumour type is being tested in combination with at least one immune checkpoint inhibitor (Figure 2A). This evidence concerns the gene PDCD1 and neoplasm.